[go: up one dir, main page]

PE20171107A1 - Anticuerpos mejorados contra il-6 - Google Patents

Anticuerpos mejorados contra il-6

Info

Publication number
PE20171107A1
PE20171107A1 PE2017000804A PE2017000804A PE20171107A1 PE 20171107 A1 PE20171107 A1 PE 20171107A1 PE 2017000804 A PE2017000804 A PE 2017000804A PE 2017000804 A PE2017000804 A PE 2017000804A PE 20171107 A1 PE20171107 A1 PE 20171107A1
Authority
PE
Peru
Prior art keywords
amino acid
acid sequence
sequence seq
cdr1
cdr2
Prior art date
Application number
PE2017000804A
Other languages
English (en)
Inventor
Michael March Schmidt
Alison Tisdale
Eric Steven Furfine
Grigorios Zarbis-Papastoitsis
Original Assignee
Eleven Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eleven Biotherapeutics Inc filed Critical Eleven Biotherapeutics Inc
Publication of PE20171107A1 publication Critical patent/PE20171107A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se refiere a un anticuerpo o fragmento de union al antigeno que comprende: una region variable de cadena pesada caracterizada porque comprende una CDR1 con una secuencia de aminoacidos SEC ID NO: 45, entre otros; una CDR2 con una secuencia de aminoacidos SEC ID NO: 46, entre otros; y una CDR3 con una secuencia de aminoacidos SEC ID NO: 33, entre otros; y una region variable de cadena ligera caracterizada porque comprende una CDR1 con una secuencia de aminoacidos SEQ ID NO: 34; una CDR2 con una secuencia de aminoacidos SEC ID NO: 35; y una CDR3 con una secuencia de aminoacidos SEC ID NO: 36. Tambien se refiere a una composicion farmaceutica, a un acido nucleico, a un vector de transferencia y a una celula hospedera. Dicho anticuerpo es especifico contra la glucoproteina IL-6, siendo util en el tratamiento de retinopatia diabetica, edema macular diabetico, entre otros.
PE2017000804A 2014-11-07 2015-11-06 Anticuerpos mejorados contra il-6 PE20171107A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462077105P 2014-11-07 2014-11-07
US201462087448P 2014-12-04 2014-12-04
US201562247705P 2015-10-28 2015-10-28

Publications (1)

Publication Number Publication Date
PE20171107A1 true PE20171107A1 (es) 2017-08-07

Family

ID=54602042

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000804A PE20171107A1 (es) 2014-11-07 2015-11-06 Anticuerpos mejorados contra il-6

Country Status (33)

Country Link
US (3) US11142571B2 (es)
EP (3) EP3215530B9 (es)
JP (1) JP6594438B2 (es)
KR (2) KR102770849B1 (es)
CN (1) CN107249631B (es)
AU (1) AU2015342882B2 (es)
CA (1) CA2965689C (es)
CL (1) CL2017001135A1 (es)
CO (1) CO2017005404A2 (es)
CR (1) CR20170231A (es)
DK (2) DK3215530T3 (es)
EA (1) EA035199B1 (es)
ES (2) ES3051832T3 (es)
FI (1) FI4268843T3 (es)
HR (2) HRP20191945T1 (es)
HU (1) HUE046181T2 (es)
IL (1) IL251858B (es)
LT (1) LT4268843T (es)
MA (2) MA62787B1 (es)
MX (2) MX385206B (es)
MY (1) MY185114A (es)
PE (1) PE20171107A1 (es)
PH (1) PH12017500809B1 (es)
PL (2) PL3215530T3 (es)
PT (2) PT4268843T (es)
RS (2) RS67353B1 (es)
SA (1) SA517381458B1 (es)
SG (2) SG10202103420PA (es)
SI (1) SI3215530T1 (es)
SM (1) SMT202500415T1 (es)
UA (1) UA122673C2 (es)
WO (1) WO2016073890A1 (es)
ZA (1) ZA201702985B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI748962B (zh) 2015-09-23 2021-12-11 美商建南德克公司 抗ｖｅｇｆ抗體之最佳化變異體
MX2018010032A (es) * 2016-02-23 2019-03-11 Sesen Bio Inc Formulaciones de antagonista de il-6 y sus usos.
MX2019007144A (es) * 2016-12-19 2019-10-07 Glenmark Pharmaceuticals Sa Nuevos agonistas de tnfr y sus usos.
WO2018175752A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Anti-interleukin-33 antibodies and uses thereof
WO2021194913A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
AU2021361108A1 (en) 2020-10-15 2023-05-25 F. Hoffmann-La Roche Ag Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery
CN114525235B (zh) * 2022-02-25 2023-07-14 郑州大学 一种提高人表皮生长因子分泌生产效率的方法
CN115343483B (zh) * 2022-08-12 2024-11-26 苏州邦器生物技术有限公司 一种自身免疫性糖尿病检测用试剂盒及其制备方法
KR20250093319A (ko) * 2022-10-24 2025-06-24 에프. 호프만-라 로슈 아게 Il-6 길항제에 대한 반응 예측

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
ATE363532T1 (de) 1991-03-01 2007-06-15 Dyax Corp Verfahren zur herstellung bindender miniproteine
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
TW311927B (es) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
EP1137941B2 (en) 1998-12-10 2013-09-11 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
CA2444854A1 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
AU2003234439A1 (en) 2002-05-07 2003-11-11 Control Delivery Systems, Inc. Processes for forming a drug delivery device
CA2506230A1 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
AU2004308482A1 (en) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Agonist anti-trkC antibodies and methods using same
DK2213683T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CA2635615A1 (en) 2005-12-30 2007-07-12 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
US20110059101A9 (en) 2006-03-13 2011-03-10 Ablynx N.V. Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
NZ572807A (en) 2006-05-19 2011-10-28 Alder Biopharmaceuticals Inc Culture method for obtaining a clonal population of antigen-specific b cells
CA2688146C (en) * 2007-05-21 2018-03-06 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
SI2198007T1 (en) 2007-09-14 2018-04-30 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing Clostridium difficile A and B toxoids
CA2705879A1 (en) 2007-11-21 2009-06-04 Amgen Inc. Wise binding agents and epitopes
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
AU2009204863B2 (en) 2008-01-15 2015-07-16 AbbVie Deutschland GmbH & Co. KG Powdered protein compositions and methods of making same
SG10201405377XA (en) 2008-08-05 2014-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
DK2324930T3 (da) 2008-09-12 2012-12-10 Kdf Co Ltd Vandsprøjteindretning
WO2010039750A2 (en) 2008-10-01 2010-04-08 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
AU2009319175A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
WO2010088444A1 (en) 2009-01-29 2010-08-05 Medimmune, Llc Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2012007896A1 (en) 2010-07-12 2012-01-19 Covx Technologies Ireland, Ltd. Multifunctional antibody conjugates
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
AU2013334740A1 (en) 2012-10-25 2015-04-02 Medimmune, Llc Stable, low viscosity antibody formulation
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
EP4374873B1 (en) 2013-07-12 2025-10-22 Astellas US LLC Agent for use in treating or preventing opthalmological conditions
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Also Published As

Publication number Publication date
EP3215530B1 (en) 2019-08-21
SMT202500415T1 (it) 2026-01-12
HRP20251312T1 (hr) 2025-12-05
RS67353B1 (sr) 2025-11-28
EA035199B1 (ru) 2020-05-14
ES2756275T3 (es) 2020-04-27
MX2021008663A (es) 2021-08-19
KR102770849B1 (ko) 2025-02-20
BR112017008672A2 (pt) 2018-03-20
MX2017005992A (es) 2017-09-15
EA201791005A1 (ru) 2017-09-29
CA2965689A1 (en) 2016-05-12
IL251858A0 (en) 2017-06-29
KR20240023450A (ko) 2024-02-21
CR20170231A (es) 2017-09-25
SG11201703574VA (en) 2017-05-30
CO2017005404A2 (es) 2017-10-31
SG10202103420PA (en) 2021-05-28
CN107249631B (zh) 2021-11-23
US20190194312A1 (en) 2019-06-27
HRP20191945T1 (hr) 2020-01-24
FI4268843T3 (fi) 2025-11-14
CL2017001135A1 (es) 2017-12-15
DK4268843T3 (da) 2025-11-10
WO2016073890A1 (en) 2016-05-12
US20250059270A1 (en) 2025-02-20
US20220169719A1 (en) 2022-06-02
IL251858B (en) 2022-09-01
EP4268843A3 (en) 2023-12-27
PH12017500809A1 (en) 2017-10-02
SA517381458B1 (ar) 2020-07-09
MX385206B (es) 2025-03-14
PL4268843T3 (pl) 2025-12-15
CN107249631A (zh) 2017-10-13
PT4268843T (pt) 2025-10-31
KR20170077196A (ko) 2017-07-05
EP3215530A1 (en) 2017-09-13
MA51554A (fr) 2020-11-18
EP4268843B1 (en) 2025-09-03
LT4268843T (lt) 2025-11-25
EP4268843A2 (en) 2023-11-01
PT3215530T (pt) 2019-11-21
ES2756275T9 (es) 2020-10-29
JP2017535285A (ja) 2017-11-30
PH12017500809B1 (en) 2023-09-20
UA122673C2 (uk) 2020-12-28
AU2015342882B2 (en) 2021-05-20
DK3215530T3 (da) 2019-11-25
HK1244008A1 (en) 2018-07-27
HUE046181T2 (hu) 2020-02-28
RS59805B1 (sr) 2020-02-28
JP6594438B2 (ja) 2019-10-23
ES3051832T3 (en) 2025-12-30
MA62787B1 (fr) 2025-11-28
ZA201702985B (en) 2019-10-30
SI3215530T1 (sl) 2020-02-28
MY185114A (en) 2021-04-30
EP3632931A1 (en) 2020-04-08
AU2015342882A1 (en) 2017-05-18
KR102636726B1 (ko) 2024-02-13
US11142571B2 (en) 2021-10-12
CA2965689C (en) 2022-03-22
PL3215530T3 (pl) 2020-05-18
EP3215530B9 (en) 2020-09-09
NZ731090A (en) 2024-03-22

Similar Documents

Publication Publication Date Title
PE20171107A1 (es) Anticuerpos mejorados contra il-6
PE20170665A1 (es) Anticuerpos anti-tau humanizados
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20142407A1 (es) Formulacion de anticuerpos
PE20150002A1 (es) Anticuerpos anti-fcrn
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20140247A1 (es) Anticuerpos anti-cd38
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20141017A1 (es) Anticuerpos del cea
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
PE20170953A1 (es) ANTICUERPOS ANTI-CD79b Y METODOS DE USO
PE20180499A1 (es) Anticuerpos de union a tau
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
PE20131209A1 (es) Anticuerpos anti-fap
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
AR085383A1 (es) Anticuerpos contra el il33r humano y usos de los mismos
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20141188A1 (es) Polipeptidos anticuerpos que antagonizan cd40
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer